May 19, 2026

ER-100 Clinical Trial: Glaucoma Trials That May Lead To Immortality. Know More

ER-100 Clinical Trial: Glaucoma Trials That May Lead To Immortality. Know More

You may have heard of the cruel and mighty Mahishasura and Hiranyakashipu from old mythological stories. They performed penance (through Tapashya or meditation) to achieve immortality. But they failed.

Even today, human beings aspire to and research to find out the secret of immortality. They are near achieving a real feat in the form of the ER-100 clinical trial for Glaucoma.

The Glaucoma clinical trial is a study on cellular rejuvenation therapy. It has received clearance from the FDA.

The research direction is slowly revealing some earth-jolting developments.

Glaucoma Treatment In India: Real Picture

• According to a study, 5% of people aged 65 and above have glaucoma. The prevalence of Glaucoma in India is about 3.23%.

• In India, glaucoma has contributed to a massive 12.08% of blindness.

• In the south of India, around 20.34% of people have heard about glaucoma.

• The worst part is that nearly 90% of glaucomas are undiagnosed.

However, if you or any of your acquaintances is suffering, you must see an eye doctor in Kolkata. If you are from the suburbs, then a glaucoma doctor in Birati, North Dumdum, may help you out.

What is ER-100?

Let’s understand all about this development. So, what is ER-100? It is a gene therapy, which scientists believe may reset damaged eye nerve cells and help beat Glaucoma.

The treatment involves some specific proteins:

• OCT4.

• SOX2.

• KLF4.

• And C-MYC.

Scientist-researchers Takahashi and Yamanaka found them out. According to them, these cells are reprogrammable in the development of adult cells. They convert senescent cells into induced pluripotent stem cells, which, in a way, mitigate signs of ageing.

The research and observation were conducted in 2006 on mice. The proteins are called the Yamanaka factors.

The Disease Against Which The Trial was Intended

The two main diseases against which scientists conducted the trials include:

NAION (Optic nerve damage or loss of blood flow to the optic nerve).
Open-Angle Glaucoma (advanced glaucoma treatment)

The main objective of the trials is to understand the immune response tolerability.

In the long run, when the test is conducted on humans, the following approach will be followed.

Firstly, around 18 participants will be inducted into the clinical trials for glaucoma patients.

The researchers will apply a single dose of ER-100 to the participants.

The doctors would be monitoring eye health and overall safety.

The patients or participants in the clinical trials will undergo blood and lab tests, and vision tests. Furthermore, they will have to pass through quality-of-life questionnaires.

The Objectives and Results of the ER-100 Clinical Trial for Glaucoma

The study was conducted by Life Biosciences. Sharon Rosenzweig, the Chief Scientific Officer, said that the research is extremely significant, and the milestone achieved is the fruit of incessant research, optimisation, and comprehensive non-human primate studies.

The benefits thus achieved from the clinical trial are the restoration of methylation patterns. Moreover, the research helped improve visual function.

The positive results paved the way for the first-in-human evaluation of the cellular rejuvenation approach.

These developments may involve the lives of elderly adults suffering from age-related diseases like optic neuropathies.

There is a Lot of Distance to be Covered

This eye pressure treatment, or vision loss prevention treatment, may go on to become a revolution in treating elderly people. The clinical trials, when becoming a real success, may help increase the life expectancy of elderly people. However, it is still under the experimental period and is not approved for public use.